Catalyst Brief

← Calendar

Readoutin 14d

Janssen Research & Development, LLC — Cetrelimab

Phase 3 primary completion: TAR-200 in combination with Cetrelimab vs chemoradiotherapy in MIBC.

Date
Dec 2026
Type
Readout
Ticker
JNJ
Indication
Muscle-invasive bladder cancer (MIBC)

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.